Aspen pockets R2bn profit as it offloads European rights to HRT drug
Read the full story on News24 BusinessAspen Pharmacare’s shares rose 2% on Monday after it announced the sale of the European rights to its menopause-treatment brand Ovestin for R3.7 billion, booking a R2 billion profit.
This story was written and published by News24 Business. Business.co.za shows its headline and teaser from the publisher’s RSS feed and links to the original.